6.95

5.62% 0.37

After Hours: 6.95

Athira Pharma Inc (ATHA)

Overview News Price History Option Chain Financials Discussions Forecast

Athira Pharma Inc stock is traded at $6.95, with a volume of 167.44K. It is up +5.62% in the last 24 hours and up +75.95% over the past month. Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

Previous Close:

$6.58

Open:

$6.57

24h Volume:

167.44K

Relative Volume:

0.17

Market Cap:

$27.41M

Revenue:

Net Income/Loss:

$-117.67M

P/E Ratio:

-2.2492

EPS:

-3.09

Net Cash Flow:

$-101.06M

1W Performance:

-1.00%

1M Performance:

+75.95%

6M Performance:

+1,944%

1Y Performance:

+1,113%

1-Day Range:

$6.50

$7.00

1-Week Range:

$6.405

$7.64

52-Week Range:

$0.2195

$8.36

Athira Pharma Inc Stock (ATHA) Company Profile

Name

Athira Pharma Inc

Sector

Healthcare (1115)

Industry

Biotechnology (624)

Phone

(425) 620-8501

Address

18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL

Employee

Twitter

Next Earnings Date

2024-12-07

Latest SEC Filings

ATHA's Discussions on Twitter

Compare ATHA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATHA Athira Pharma Inc	6.95	25.95M	0	-117.67M	-101.06M	-3.09
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-19-24	Downgrade	Mizuho	Outperform → Neutral
Sep-04-24	Downgrade	BTIG Research	Buy → Neutral
Sep-04-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-24	Downgrade	Rodman & Renshaw	Buy → Neutral
Aug-19-24	Initiated	Rodman & Renshaw	Buy
Oct-17-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Jul-07-22	Initiated	Mizuho	Buy
Jun-23-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-23-22	Downgrade	Jefferies	Buy → Hold
Jun-23-22	Downgrade	Stifel	Buy → Hold
May-10-22	Initiated	BTIG Research	Buy
Apr-21-22	Initiated	Berenberg	Buy
Dec-15-21	Initiated	Goldman	Neutral
Oct-13-20	Initiated	Goldman	Buy
Oct-13-20	Initiated	JMP Securities	Mkt Outperform
Oct-13-20	Initiated	Jefferies	Buy
Oct-13-20	Initiated	Stifel	Buy

View All

Athira Pharma Inc Stock (ATHA) Latest News

05:27 AM

Athira Pharma (NASDAQ:ATHA) CEO Mark James Litton Sells 2,586 Shares - Defense World

05:27 AM

Jan 05, 2026

Worthington, Athira Pharma general counsel, sells $6k in ATHA stock - Investing.com Canada

Jan 05, 2026

Athira Pharma CSO Church sells $6k in ATHA stock - Investing.com

Jan 05, 2026

Jan 02, 2026

Aug Analyst Calls: How 1CM Inc IQ70 stock performs during market turbulence2025 Retail Activity & Short-Term Trading Opportunity Alerts - moha.gov.vn

Jan 02, 2026

Jan 01, 2026

Athira Pharma CSO Church sells $6k in ATHA stock By Investing.com - Investing.com Nigeria

Jan 01, 2026

Dec 29, 2025

Immix Biopharma (NASDAQ:IMMX) & Athira Pharma (NASDAQ:ATHA) Critical Survey - Defense World

Dec 29, 2025

Dec 23, 2025

Athira Pharma Stock Rockets 92% With 5-Day Winning Streak - Trefis

Dec 23, 2025

Dec 22, 2025

Athira Pharma Licenses Lasofoxifene For Metastatic Breast Cancer, Secures $236 Million Funding - Voice Of HealthCare

Dec 22, 2025

Dec 21, 2025

Athira Pharma recovers from Alzheimer’s failure with breast cancer pivot and $90M investment - MSN

Dec 21, 2025

Dec 20, 2025

Why retail investors favor Athira Pharma Inc. stockQuarterly Portfolio Review & Consistent Return Investment Signals - Улправда

Dec 20, 2025

How strong is Athira Pharma Inc. stock balance sheetMarket Sentiment Report & Weekly High Return Stock Opportunities - bolumsonucanavari.com

Dec 20, 2025

Can Athira Pharma Inc. stock beat analyst upgradesTrade Signal Summary & Precise Buy Zone Identification - Улправда

Dec 20, 2025

Dec 19, 2025

Does Athira Pharma Inc. stock trade at a discount to peersJuly 2025 Big Picture & Daily Volume Surge Signals - Улправда

Dec 19, 2025

Volume Summary: Why retail investors favor Athira Pharma Inc. stockJuly 2025 Technicals & AI Powered Market Entry Ideas - Улправда

Dec 19, 2025